NewSquare Capital’s Corvus Pharmaceuticals CRVS Stock Holding History

NewSquare Capital’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-220	Closed	-$504	–	657
2023 Q2	$504	Buy	+220	New	+$457	﹤0.01%	683

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TowerView LLC New York $155M AUM 30.14% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

NewSquare Capital's CRVS Position: Q3 2023 in Review

NewSquare Capital sold out of Corvus Pharmaceuticals (CRVS) in Q3 2023, closing a stake of 220 shares — an estimated $504 sold.

NewSquare Capital first reported a position in CRVS in Q2 2023 and held it in 1 quarter. The position peaked at $504 in Q2 2023. 52 funds tracked by Wall St. Rank hold CRVS as of Q3 2023.

NewSquare Capital reported no remaining Corvus Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
NewSquare Capital sold 220 Corvus Pharmaceuticals shares in Q3 2023, an estimated $504.
NewSquare Capital first reported a position in Corvus Pharmaceuticals in Q2 2023 and held it in 1 quarter.
NewSquare Capital's Corvus Pharmaceuticals position peaked at $504 in Q2 2023.
52 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.